IP Library Granted Patent US 12709747
Granted Patent B2
US 12709747 · App. 18/475,879 · Granted Aug 18, 2026

Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Inventors: Anthony D. Duong (Columbus, OH); Danielle J. Huk (Hilliard, OH); Cherry Gupta (Columbus, OH); Kenneth R. Sims, Jr. (Delaware, OH); Michael S. Koeris (Irvine, CA); Zachary R. Shank (London, OH); Ashlee J. Colbert (Blacklick, OH); Andrea D. McCue (Columbus, OH); Emma K. Schmitz (Columbus, OH); Caleb T. Hillrich (Columbus, OH); Shannon D. Miller (Hilliard, OH); Joanna L. Hoy (Columbus, OH)
Assignee: BATTELLE MEMORIAL INSTITUTE
C12N15/1065A61K48/0041A61K48/0091C12N15/88C12Q1/6804C12Q1/6816C12Q1/682C12Q2525/301C12Q2525/313G01N33/5308
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709747
App. No.
18/475,879
Granted
Aug 18, 2026
Kind
B2
Abstract

The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.

Claims (31)

1 . A composition comprising:

a non-viral delivery vehicle comprising one or more nanoparticle forming polymers, and

a nucleic acid construct, comprising:

two primer binding segments; and

one or more unique polynucleotide barcodes between the two primer binding segments,

wherein the nucleic acid construct is:

electrostatically associated with the nanoparticle forming polymers;

bonded to the nanoparticle forming polymers via complexation of biotin and a biotin binding molecule; or

covalently bonded to the nanoparticle forming polymers,

wherein the one or more nanoparticle forming polymers are RAFT block copolymers comprising:

a. a first terminus comprising a first capping unit derived from a first chain transfer agent in a RAFT copolymerization process;

b. a first block prepared from one or more monomer units covalently attached to the first reactive functional unit, and having a molecular weight (M n ) in the range of about 1 kDa to about 200 kDa and a degree of polymerization in the range of about 10 to about 2500;

c. optionally a second block prepared from one or more monomer units covalently attached to the first block, and having a molecular weight (M n ) in the range of about 1 kDa to about 200 kDa and a degree of polymerization in the range of about 20 to about 2000; and

d. a second terminus comprising a second capping unit derived from a first or a second chain transfer agent.

2 . The composition of claim 1 , wherein the non-viral delivery vehicle has one or more of an overall molecular weight (M n ) in the range of about 25 kDa to about 60 kDa, an overall degree of polymerization in the range of about 700 to about 900, a target size in the range of about of about 10 to about 60 nm, and a maximum corona-to-core ratio (CCR) of about 1.5 to about 3.5.

3 . The composition of claim 1 , wherein the first block is prepared from one or more monomer units selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl) methacrylate, and methyl methacrylate.

4 . The composition of claim 1 , wherein the first block is prepared from one of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxyethyl) methacrylate, or methyl methacrylate.

5 . The composition of claim 1 , wherein the second block is prepared from one or more monomer units selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxy ethyl methacrylate, and methyl methacrylate.

6 . The composition of claim 1 , wherein the second block is a random copolymer prepared from two different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, hydroxy ethyl methacrylate, and methyl methacrylate.

7 . The composition of claim 1 , wherein the second block is a random copolymer prepared from three different monomer units independently selected from the group consisting of 2-dimethylaminoethyl acrylate, 2-(diethylamino) ethyl methacrylate, 2-(diisopropylamino) ethyl methacrylate, butyl methacrylate, ethyl acrylic acid, propyl acrylic acid, (hydroxy ethyl) methacrylate, and methyl methacrylate.

8 . The composition of claim 1 , wherein the second block is a random copolymer prepared from 2-dimethylaminoethyl acrylate, butyl methacrylate, and propyl acrylic acid; or 2-dimethylaminoethyl acrylate and butyl methacrylate; or 2-dimethylaminoethyl acrylate, butyl methacrylate, and ethyl acrylic acid.

9 . The composition of claim 1 , wherein the nucleic acid construct is electrostatically associated with the nanoparticle forming polymers.

10 . The composition of claim 1 , wherein the nucleic acid construct is bonded to the nanoparticle forming polymers via complexation of biotin and a biotin binding molecule.

11 . The composition of claim 1 , wherein the nucleic acid construct is covalently bonded to the nanoparticle forming polymers.

12 . The composition of claim 1 , wherein the primer binding segments range in length from about 15 base pairs to about 30 base pairs.

13 . The composition of claim 1 , wherein the primer binding segments are a universal primer binding set.

14 . The composition of claim 1 , wherein the one or more polynucleotide barcodes comprise unique sequences of 6-20 nucleotides in length.

15 . The composition of claim 14 , wherein the polynucleotide barcodes further comprise a hamming distance of at least 2-6 bases between any two unique polynucleotide barcode sequences.

16 . The composition of claim 1 , wherein the nucleic acid construct further comprises from about 6 to about 12 random bases at the 3′ end of the polynucleotide barcode.

17 . The composition of claim 16 , wherein the about 6 to about 12 random bases at the 3′ end of the polynucleotide barcode are for bioinformatic removal of PCR duplicates.

18 . The composition of claim 1 , wherein the nucleic acid construct ranges in length from about 42 nucleotides to about 210 nucleotides.